Abstract: The
PI mutations, L101,
V82A, and
L90M, were found in 10.5, 3 and 4% of cases, respectively; whereas for
RT, primary mutations at positions
T215Y (zidovudine),
M184V (lamivudine),
T69D/A (zalcitabine), and
K103N (multi-
NNRTI) were present in 8, 5, 4, and 4% of subjects, respectively.